Tham khảo Deferasirox

  1. ↑ “Material Safety Data Sheet (MSDS): Deferasirox”. ChemSrc. 2018. 
  2. ↑ “EXJADE (deferasirox)”. Novartis AG. 
  3. 1 2 Choudhry VP, Naithani R (tháng 8 năm 2007). “Current status of iron overload and chelation with deferasirox”. Indian Journal of Pediatrics 74 (8): 759–64. PMID 17785900. doi:10.1007/s12098-007-0134-7.  Free full text Error in Webarchive template: Empty url.
  4. ↑ Yang LP, Keam SJ, Keating GM (2007). “Deferasirox: a review of its use in the management of transfusional chronic iron overload”. Drugs 67 (15): 2211–30. PMID 17927285. doi:10.2165/00003495-200767150-00007. 
  5. 1 2 “FDA Approves First Oral Drug for Chronic Iron Overload” (Thông cáo báo chí). United States Food and Drug Administration. 9 tháng 11 năm 2005. Truy cập ngày 31 tháng 10 năm 2007. 
  6. ↑ “Exjade – deferasirox” (PDF). European Medicines Agency. 2018. 
  7. ↑ Kontoghiorghes GJ (tháng 4 năm 2013). “Turning a blind eye to deferasirox's toxicity?”. Lancet 381 (9873): 1183–4. PMID 23561999. doi:10.1016/S0140-6736(13)60799-0. 
  8. ↑ Steinhauser S, Heinz U, Bartholomä M, Weyhermüller T, Nick H, Hegetschweiler K (2004). “Complex Formation of ICL670 and Related Ligands with FeIII and FeII”. European Journal of Inorganic Chemistry 2004 (21): 4177–4192. doi:10.1002/ejic.200400363. ]
  9. ↑ ISMP (2010). “ISMP QuarterWatch(TM)” 15 (12). ISMP Medication Safety Alert. tr. 1–3.